Intermittent or Continuous FOLFIRI + Panitumumab RAS and BRAF Wild-Type Metastatic CRC - OncoDaily

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INF...

Moving towards more personalized approaches in locally advanced and metastatic colorectal cancer - Nature Reviews Gastroenterology & Hepatology

FEBS Press

Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping

2024 FDA approvals

FDA grants accelerated approval

FDA grants accelerated approval

ClinicalTrials.gov

Accelerating Innovation in Biliary Tract Cancer | LinkedIn

ctDNA, Neoadjuvant Immunotherapy Combos Could Help Reshape Management of CRC

Systemic Therapy for Stage I-III Anal Squamous Cell Carcinoma: ASCO Guideline

Rachna T. Shroff: SWOG S1815 shows no OS benefit for nab-paclitaxel in BTCs - OncoDaily

Medical.watch

Nivolumab/Ipilimumab vs Chemotherapy With or Without Targeted Agents in MSI-H or dMMR Metastatic Colorectal Cancer

2024 Top Story in Oncology: The Role of Radiotherapy in Operable Gastro-Oesophageal and Gastric Cancer — Time for Change

Highlights from Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Day 2 - OncoDaily

Three new Pan-Asian-adapted guidelines at ESMO Asia Congress

Negative Screening Results and Colorectal Cancer

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial | Journal of Cli...